Paul Phillips
Concepts (247)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Diplopia | 7 | 2017 | 22 | 2.580 |
Why?
| Exotropia | 7 | 2023 | 15 | 2.320 |
Why?
| Oculomotor Muscles | 5 | 2019 | 31 | 2.160 |
Why?
| Ocular Motility Disorders | 5 | 2018 | 21 | 2.120 |
Why?
| Ophthalmologic Surgical Procedures | 4 | 2019 | 27 | 2.030 |
Why?
| Pseudotumor Cerebri | 6 | 2018 | 24 | 1.940 |
Why?
| Optic Nerve | 6 | 2014 | 46 | 1.810 |
Why?
| Papilledema | 5 | 2022 | 28 | 1.600 |
Why?
| Intracranial Pressure | 5 | 2019 | 32 | 1.500 |
Why?
| Hypopituitarism | 4 | 2014 | 16 | 1.350 |
Why?
| Magnetic Resonance Imaging | 14 | 2018 | 1604 | 1.270 |
Why?
| Strabismus | 5 | 2019 | 19 | 1.220 |
Why?
| Ophthalmology | 2 | 2023 | 40 | 1.110 |
Why?
| Intracranial Hypertension | 3 | 2019 | 31 | 1.110 |
Why?
| Pituitary Gland | 3 | 2014 | 78 | 1.100 |
Why?
| Eye Abnormalities | 3 | 2014 | 22 | 1.070 |
Why?
| Vision, Binocular | 4 | 2019 | 17 | 1.060 |
Why?
| Oculomotor Nerve Diseases | 2 | 2017 | 6 | 1.040 |
Why?
| Vision, Low | 2 | 2018 | 8 | 0.970 |
Why?
| Child | 26 | 2023 | 7337 | 0.950 |
Why?
| Fixation, Ocular | 3 | 2019 | 20 | 0.870 |
Why?
| Eye Diseases, Hereditary | 2 | 2017 | 6 | 0.820 |
Why?
| Optic Nerve Diseases | 2 | 2017 | 27 | 0.790 |
Why?
| Tomography, Optical Coherence | 5 | 2022 | 148 | 0.770 |
Why?
| Dyslexia | 2 | 2018 | 56 | 0.760 |
Why?
| Distance Perception | 1 | 2019 | 4 | 0.730 |
Why?
| Humans | 57 | 2024 | 54246 | 0.730 |
Why?
| Postoperative Complications | 3 | 2015 | 1033 | 0.680 |
Why?
| Orthoptics | 1 | 2018 | 4 | 0.660 |
Why?
| Abducens Nerve Diseases | 1 | 2017 | 6 | 0.610 |
Why?
| Optic Disk | 1 | 2017 | 25 | 0.600 |
Why?
| Child, Preschool | 18 | 2023 | 4146 | 0.590 |
Why?
| Apraxias | 3 | 2013 | 11 | 0.590 |
Why?
| Cavernous Sinus | 2 | 2011 | 15 | 0.590 |
Why?
| Retinal Hemorrhage | 3 | 2023 | 16 | 0.560 |
Why?
| Male | 31 | 2023 | 27312 | 0.550 |
Why?
| Eyeglasses | 3 | 2023 | 10 | 0.550 |
Why?
| Diagnosis, Differential | 9 | 2018 | 1136 | 0.510 |
Why?
| Female | 30 | 2023 | 28418 | 0.490 |
Why?
| Nervous System Diseases | 2 | 2005 | 97 | 0.490 |
Why?
| Adolescent | 13 | 2022 | 6885 | 0.490 |
Why?
| Developmental Disabilities | 2 | 2013 | 126 | 0.440 |
Why?
| Meningitis, Cryptococcal | 1 | 2012 | 12 | 0.430 |
Why?
| Blepharoptosis | 1 | 2012 | 15 | 0.430 |
Why?
| Cryptococcus neoformans | 1 | 2012 | 28 | 0.420 |
Why?
| Retinal Diseases | 2 | 2024 | 49 | 0.420 |
Why?
| Carotid Artery, Internal, Dissection | 1 | 2011 | 8 | 0.410 |
Why?
| Visual Acuity | 8 | 2019 | 143 | 0.410 |
Why?
| Brain Diseases | 2 | 2012 | 87 | 0.400 |
Why?
| Tuberous Sclerosis | 1 | 2011 | 37 | 0.390 |
Why?
| Intracranial Aneurysm | 1 | 2011 | 54 | 0.390 |
Why?
| Neurofibromatosis 1 | 1 | 2010 | 29 | 0.380 |
Why?
| Infant | 10 | 2023 | 3817 | 0.370 |
Why?
| Hemianopsia | 1 | 2009 | 6 | 0.350 |
Why?
| Optic Disk Drusen | 1 | 2009 | 4 | 0.340 |
Why?
| Cerebrospinal Fluid Shunts | 1 | 2008 | 19 | 0.340 |
Why?
| Dyskeratosis Congenita | 1 | 2008 | 3 | 0.330 |
Why?
| Rhombencephalon | 1 | 2007 | 4 | 0.320 |
Why?
| Adrenoleukodystrophy | 1 | 2007 | 1 | 0.320 |
Why?
| Cerebellum | 2 | 2013 | 142 | 0.320 |
Why?
| Botulinum Toxins | 1 | 2007 | 5 | 0.310 |
Why?
| Retrospective Studies | 8 | 2023 | 6432 | 0.300 |
Why?
| Fluorescein Angiography | 2 | 2022 | 30 | 0.270 |
Why?
| Cerebrospinal Fluid Pressure | 2 | 2016 | 4 | 0.250 |
Why?
| Craniocerebral Trauma | 2 | 2023 | 89 | 0.240 |
Why?
| Retirement | 1 | 2023 | 18 | 0.230 |
Why?
| Diabetic Retinopathy | 1 | 2024 | 41 | 0.230 |
Why?
| Optic Chiasm | 1 | 2003 | 8 | 0.230 |
Why?
| Optic Atrophy, Hereditary, Leber | 1 | 2003 | 5 | 0.230 |
Why?
| Retinal Ganglion Cells | 1 | 2022 | 23 | 0.220 |
Why?
| Forecasting | 1 | 2023 | 161 | 0.220 |
Why?
| Young Adult | 5 | 2019 | 4308 | 0.220 |
Why?
| Central Nervous System Neoplasms | 1 | 2023 | 57 | 0.220 |
Why?
| Meningeal Neoplasms | 1 | 2023 | 50 | 0.210 |
Why?
| Adult | 10 | 2019 | 14182 | 0.210 |
Why?
| Charcot-Marie-Tooth Disease | 1 | 2022 | 11 | 0.210 |
Why?
| Anesthetics, Combined | 1 | 2001 | 2 | 0.210 |
Why?
| Optic Atrophy | 1 | 2022 | 18 | 0.210 |
Why?
| Anesthesia, Local | 1 | 2001 | 19 | 0.210 |
Why?
| Ophthalmoscopy | 2 | 2013 | 19 | 0.200 |
Why?
| Giant Cell Arteritis | 1 | 2021 | 12 | 0.200 |
Why?
| Phacoemulsification | 1 | 2001 | 30 | 0.200 |
Why?
| Brain Injuries | 1 | 2023 | 183 | 0.200 |
Why?
| Orbital Diseases | 1 | 2001 | 13 | 0.200 |
Why?
| Anesthetics, Local | 1 | 2001 | 74 | 0.200 |
Why?
| Vision Tests | 3 | 2023 | 16 | 0.200 |
Why?
| Prospective Studies | 4 | 2019 | 2604 | 0.190 |
Why?
| Macular Degeneration | 1 | 2021 | 49 | 0.190 |
Why?
| Choroiditis | 1 | 2020 | 10 | 0.190 |
Why?
| Follow-Up Studies | 4 | 2019 | 2387 | 0.190 |
Why?
| Multiple Sclerosis | 1 | 2021 | 72 | 0.190 |
Why?
| Child Abuse | 1 | 2023 | 170 | 0.190 |
Why?
| Socioeconomic Factors | 1 | 2023 | 637 | 0.190 |
Why?
| Health Status Disparities | 1 | 2023 | 219 | 0.190 |
Why?
| Aged | 5 | 2021 | 10041 | 0.180 |
Why?
| Vitreoretinal Surgery | 1 | 2019 | 8 | 0.180 |
Why?
| Crohn Disease | 1 | 2020 | 96 | 0.180 |
Why?
| Arteriovenous Fistula | 1 | 1999 | 26 | 0.180 |
Why?
| Healthcare Disparities | 1 | 2023 | 268 | 0.180 |
Why?
| Carotid Artery Diseases | 1 | 1999 | 38 | 0.180 |
Why?
| Mutation | 3 | 2017 | 1501 | 0.170 |
Why?
| Middle Aged | 5 | 2019 | 13070 | 0.170 |
Why?
| Retina | 2 | 2024 | 64 | 0.170 |
Why?
| Laser Therapy | 1 | 2019 | 91 | 0.170 |
Why?
| Sensitivity and Specificity | 2 | 2013 | 923 | 0.170 |
Why?
| Astigmatism | 1 | 2018 | 6 | 0.170 |
Why?
| Amblyopia | 1 | 2018 | 6 | 0.170 |
Why?
| Mydriatics | 1 | 2018 | 14 | 0.160 |
Why?
| Imaging, Three-Dimensional | 1 | 2019 | 171 | 0.160 |
Why?
| Pupil | 1 | 2018 | 32 | 0.160 |
Why?
| Sinus Thrombosis, Intracranial | 1 | 2018 | 20 | 0.160 |
Why?
| Accommodation, Ocular | 1 | 2017 | 5 | 0.160 |
Why?
| Convergence, Ocular | 1 | 2017 | 4 | 0.160 |
Why?
| Glucose Transport Proteins, Facilitative | 1 | 2017 | 10 | 0.160 |
Why?
| Keratoconus | 1 | 2017 | 4 | 0.160 |
Why?
| Myopia | 1 | 2017 | 8 | 0.160 |
Why?
| Reading | 1 | 2018 | 84 | 0.150 |
Why?
| Skin Diseases, Genetic | 1 | 2017 | 11 | 0.150 |
Why?
| Obesity | 3 | 2016 | 1197 | 0.150 |
Why?
| Heterozygote | 1 | 2017 | 96 | 0.150 |
Why?
| Minocycline | 1 | 2017 | 18 | 0.150 |
Why?
| Subarachnoid Hemorrhage | 1 | 2018 | 65 | 0.150 |
Why?
| Cornea | 1 | 2017 | 62 | 0.150 |
Why?
| Vision Disorders | 1 | 2017 | 73 | 0.150 |
Why?
| Carbonic Anhydrase Inhibitors | 1 | 2016 | 5 | 0.150 |
Why?
| Arteries | 1 | 2017 | 101 | 0.150 |
Why?
| Joint Instability | 1 | 2017 | 59 | 0.150 |
Why?
| United States | 3 | 2023 | 5200 | 0.150 |
Why?
| Syndrome | 1 | 2017 | 252 | 0.150 |
Why?
| Acetazolamide | 1 | 2016 | 20 | 0.140 |
Why?
| Cross-Sectional Studies | 3 | 2023 | 1679 | 0.140 |
Why?
| Depth Perception | 2 | 2005 | 8 | 0.140 |
Why?
| Attention Deficit Disorder with Hyperactivity | 1 | 2018 | 231 | 0.140 |
Why?
| Vascular Malformations | 1 | 2017 | 101 | 0.130 |
Why?
| Nevus of Ota | 1 | 2014 | 3 | 0.130 |
Why?
| Scleral Diseases | 1 | 2014 | 3 | 0.130 |
Why?
| Eye Neoplasms | 1 | 2014 | 10 | 0.130 |
Why?
| Aged, 80 and over | 2 | 2019 | 3429 | 0.130 |
Why?
| Chi-Square Distribution | 2 | 2005 | 318 | 0.130 |
Why?
| Siblings | 1 | 2014 | 37 | 0.130 |
Why?
| Functional Laterality | 1 | 2014 | 99 | 0.120 |
Why?
| Cogan Syndrome | 1 | 2013 | 2 | 0.120 |
Why?
| Kidney Diseases, Cystic | 1 | 2013 | 20 | 0.120 |
Why?
| Cerebellar Diseases | 1 | 2013 | 18 | 0.120 |
Why?
| Sex Factors | 2 | 2016 | 765 | 0.120 |
Why?
| Body Mass Index | 1 | 2016 | 712 | 0.110 |
Why?
| Treatment Outcome | 3 | 2019 | 5604 | 0.110 |
Why?
| Optic Nerve Neoplasms | 2 | 2004 | 8 | 0.110 |
Why?
| Stroke | 1 | 2018 | 524 | 0.110 |
Why?
| Adaptor Proteins, Signal Transducing | 1 | 2013 | 208 | 0.110 |
Why?
| Myasthenia Gravis | 1 | 2012 | 17 | 0.110 |
Why?
| Case-Control Studies | 2 | 2005 | 1228 | 0.110 |
Why?
| Orbit | 2 | 2003 | 35 | 0.100 |
Why?
| Visual Fields | 2 | 2009 | 56 | 0.100 |
Why?
| Risk Assessment | 1 | 2016 | 1361 | 0.100 |
Why?
| Anti-Bacterial Agents | 1 | 2017 | 820 | 0.100 |
Why?
| Risk Factors | 2 | 2016 | 3930 | 0.100 |
Why?
| Membrane Proteins | 1 | 2013 | 389 | 0.090 |
Why?
| Acute Disease | 2 | 2021 | 403 | 0.090 |
Why?
| Reproducibility of Results | 1 | 2013 | 1304 | 0.090 |
Why?
| Optic Nerve Injuries | 1 | 2009 | 8 | 0.090 |
Why?
| Paranasal Sinuses | 1 | 2009 | 25 | 0.090 |
Why?
| Decompression, Surgical | 1 | 2009 | 52 | 0.080 |
Why?
| Skin Neoplasms | 1 | 2014 | 532 | 0.080 |
Why?
| Equipment Failure | 1 | 2008 | 70 | 0.080 |
Why?
| Hydrocephalus | 1 | 2008 | 41 | 0.080 |
Why?
| Endoscopy | 1 | 2009 | 131 | 0.080 |
Why?
| Blood Transfusion | 1 | 2008 | 138 | 0.070 |
Why?
| Tomography, X-Ray Computed | 2 | 2009 | 1213 | 0.070 |
Why?
| DNA, Mitochondrial | 2 | 2003 | 186 | 0.060 |
Why?
| Age Factors | 2 | 2019 | 1195 | 0.060 |
Why?
| Methylprednisolone | 2 | 2018 | 38 | 0.060 |
Why?
| Prognosis | 1 | 2010 | 2118 | 0.060 |
Why?
| Neuronal Ceroid-Lipofuscinoses | 1 | 2004 | 6 | 0.060 |
Why?
| Chromosomes, Human, Pair 15 | 1 | 2004 | 9 | 0.060 |
Why?
| Retinal Degeneration | 1 | 2004 | 16 | 0.060 |
Why?
| Exons | 1 | 2004 | 105 | 0.060 |
Why?
| Refraction, Ocular | 1 | 2023 | 9 | 0.060 |
Why?
| Molecular Chaperones | 1 | 2004 | 64 | 0.060 |
Why?
| Cultural Diversity | 1 | 2023 | 30 | 0.060 |
Why?
| Optic Atrophies, Hereditary | 1 | 2003 | 2 | 0.060 |
Why?
| Hematoma, Subdural | 1 | 2023 | 27 | 0.060 |
Why?
| Hypertrophy | 1 | 2003 | 52 | 0.060 |
Why?
| Schools, Medical | 1 | 2023 | 82 | 0.060 |
Why?
| Chromosome Deletion | 1 | 2004 | 150 | 0.060 |
Why?
| Ischemia | 1 | 2024 | 177 | 0.060 |
Why?
| Faculty, Medical | 1 | 2023 | 100 | 0.050 |
Why?
| DNA Mutational Analysis | 1 | 2003 | 217 | 0.050 |
Why?
| Biopsy | 2 | 2021 | 692 | 0.050 |
Why?
| Membrane Glycoproteins | 1 | 2004 | 269 | 0.050 |
Why?
| Needlestick Injuries | 1 | 2001 | 6 | 0.050 |
Why?
| Pituitary Hormones | 1 | 2001 | 18 | 0.050 |
Why?
| Carcinoma, Non-Small-Cell Lung | 1 | 2004 | 164 | 0.050 |
Why?
| Lens Implantation, Intraocular | 1 | 2001 | 22 | 0.050 |
Why?
| Scotoma | 1 | 2021 | 8 | 0.050 |
Why?
| Fundus Oculi | 1 | 2021 | 24 | 0.050 |
Why?
| Bupivacaine | 1 | 2001 | 28 | 0.050 |
Why?
| Temporal Arteries | 1 | 2021 | 15 | 0.050 |
Why?
| Spinal Puncture | 2 | 2018 | 20 | 0.050 |
Why?
| Lidocaine | 1 | 2001 | 48 | 0.050 |
Why?
| Visual Pathways | 1 | 2001 | 10 | 0.050 |
Why?
| Graves Disease | 1 | 2001 | 23 | 0.050 |
Why?
| Mucormycosis | 1 | 2001 | 28 | 0.050 |
Why?
| Macrophages | 1 | 2024 | 405 | 0.050 |
Why?
| Eye Infections, Fungal | 1 | 2001 | 22 | 0.050 |
Why?
| Intravitreal Injections | 1 | 2020 | 40 | 0.050 |
Why?
| Saccades | 1 | 2000 | 5 | 0.050 |
Why?
| Pilot Projects | 1 | 2023 | 808 | 0.050 |
Why?
| Pedigree | 1 | 2000 | 146 | 0.050 |
Why?
| Aspergillosis | 1 | 2001 | 127 | 0.050 |
Why?
| Vascular Endothelial Growth Factor A | 1 | 2020 | 230 | 0.040 |
Why?
| Trochlear Nerve | 1 | 1999 | 1 | 0.040 |
Why?
| Ophthalmoplegia | 1 | 1999 | 12 | 0.040 |
Why?
| Cranial Nerve Diseases | 1 | 1999 | 14 | 0.040 |
Why?
| Postoperative Care | 1 | 2019 | 121 | 0.040 |
Why?
| Angiogenesis Inhibitors | 1 | 2020 | 203 | 0.040 |
Why?
| Refractive Errors | 1 | 2018 | 7 | 0.040 |
Why?
| Cyclopentolate | 1 | 2018 | 6 | 0.040 |
Why?
| Tropicamide | 1 | 2018 | 7 | 0.040 |
Why?
| Phenylephrine | 1 | 2018 | 34 | 0.040 |
Why?
| Equipment Design | 1 | 2019 | 318 | 0.040 |
Why?
| Drug Combinations | 1 | 2018 | 128 | 0.040 |
Why?
| Phlebography | 1 | 2018 | 70 | 0.040 |
Why?
| Corneal Topography | 1 | 2017 | 6 | 0.040 |
Why?
| Corneal Pachymetry | 1 | 2017 | 7 | 0.040 |
Why?
| Dilatation, Pathologic | 1 | 2017 | 22 | 0.040 |
Why?
| Lung Neoplasms | 1 | 2004 | 642 | 0.040 |
Why?
| Sexual Maturation | 1 | 2016 | 13 | 0.040 |
Why?
| Sex Distribution | 1 | 2016 | 158 | 0.040 |
Why?
| Age Distribution | 1 | 2016 | 198 | 0.040 |
Why?
| Morbidity | 1 | 2016 | 149 | 0.030 |
Why?
| Glucocorticoids | 1 | 2018 | 234 | 0.030 |
Why?
| Disease Progression | 1 | 2018 | 913 | 0.030 |
Why?
| Cytoskeletal Proteins | 1 | 2013 | 58 | 0.030 |
Why?
| Abnormalities, Multiple | 1 | 2013 | 159 | 0.030 |
Why?
| Blindness | 1 | 2009 | 32 | 0.020 |
Why?
| Recovery of Function | 1 | 2009 | 222 | 0.020 |
Why?
| Brain | 2 | 2004 | 1387 | 0.020 |
Why?
| Electroretinography | 1 | 2004 | 20 | 0.020 |
Why?
| Microscopy, Electron | 1 | 2004 | 97 | 0.010 |
Why?
| Neurologic Examination | 1 | 2004 | 76 | 0.010 |
Why?
| Alleles | 1 | 2004 | 277 | 0.010 |
Why?
| Polymerase Chain Reaction | 1 | 2004 | 531 | 0.010 |
Why?
| Electroencephalography | 1 | 2004 | 356 | 0.010 |
Why?
| Hemorrhage | 1 | 2003 | 208 | 0.010 |
Why?
| Skin | 1 | 2004 | 469 | 0.010 |
Why?
| Muscle, Skeletal | 1 | 2004 | 847 | 0.010 |
Why?
|
|
Phillips's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|